LRRC32 and neoplasm: Despite clear proof that our probe is selectively targeting GARP+ cells in vivo, our results demonstrate only a very slight increase in tumour uptake of the GARP targeted probe compared to the isotype control thus confirming that GARP targeting may not be sufficient to outperform the EPR effect.